137 related articles for article (PubMed ID: 25374909)
21. Chemoprevention using dutasteride: the REDUCE trial.
Gomella LG
Curr Opin Urol; 2005 Jan; 15(1):29-32. PubMed ID: 15586026
[TBL] [Abstract][Full Text] [Related]
22. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
23. Dutasteride prevents the growth response to testosterone in benign and androgen-sensitive malignant prostate cells.
Alisky JM; Tang Y; Habermehl GK; Iczkowski KA
Int J Clin Exp Med; 2010 Jul; 3(3):245-7. PubMed ID: 20827322
[TBL] [Abstract][Full Text] [Related]
24. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
Festuccia C; Gravina GL; Muzi P; Pomante R; Angelucci A; Vicentini C; Bologna M
J Urol; 2008 Jul; 180(1):367-72. PubMed ID: 18499161
[TBL] [Abstract][Full Text] [Related]
25. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
26. Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.
Seiler D; Zheng J; Liu G; Wang S; Yamashiro J; Reiter RE; Huang J; Zeng G
Prostate; 2013 Sep; 73(13):1378-90. PubMed ID: 23728788
[TBL] [Abstract][Full Text] [Related]
27. Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer.
Shao TC; Li H; Ittmann M; Cunningham GR
J Urol; 2007 Oct; 178(4 Pt 1):1521-7. PubMed ID: 17707058
[TBL] [Abstract][Full Text] [Related]
28. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
29. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
Ku JY; Lee JZ; Ha HK
Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
[TBL] [Abstract][Full Text] [Related]
30. Proliferative effect of androst-4-ene-3,17-dione and its metabolites in the androgen-sensitive LNCaP cell line.
Laplante Y; Poirier D
Steroids; 2008 Mar; 73(3):266-71. PubMed ID: 18082864
[TBL] [Abstract][Full Text] [Related]
31. Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride.
Schmidt LJ; Murillo H; Tindall DJ
J Androl; 2004; 25(6):944-53. PubMed ID: 15477368
[TBL] [Abstract][Full Text] [Related]
32. Combination of 5α-reductase inhibitor with combined androgen blockade (CAB) as a novel cytoreductive regimen before prostate brachytherapy: Ultra-CAB.
Muro Y; Kosaka T; Mizuno R; Ohashi T; Shigematsu N; Oya M
Am J Clin Exp Urol; 2015; 3(1):48-50. PubMed ID: 26069888
[TBL] [Abstract][Full Text] [Related]
33. [Dutasteride in the treatment of hormone refractory prostate cancer].
Arena F
Minerva Urol Nefrol; 2008 Jun; 60(2):71-6. PubMed ID: 18500220
[TBL] [Abstract][Full Text] [Related]
34. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride.
Umekita Y; Hiipakka RA; Kokontis JM; Liao S
Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11802-7. PubMed ID: 8876218
[TBL] [Abstract][Full Text] [Related]
35. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Andriole GL; Humphrey P; Ray P; Gleave ME; Trachtenberg J; Thomas LN; Lazier CB; Rittmaster RS
J Urol; 2004 Sep; 172(3):915-9. PubMed ID: 15310997
[TBL] [Abstract][Full Text] [Related]
36. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Musquera M; Fleshner NE; Finelli A; Zlotta AR
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
[TBL] [Abstract][Full Text] [Related]
37. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase.
Wright AS; Douglas RC; Thomas LN; Lazier CB; Rittmaster RS
Endocrinology; 1999 Oct; 140(10):4509-15. PubMed ID: 10499505
[TBL] [Abstract][Full Text] [Related]
38. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
Traish AM
Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
[TBL] [Abstract][Full Text] [Related]
39. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
40. Potential impact of combined inhibition of 3α-oxidoreductases and 5α-reductases on prostate cancer.
Fiandalo MV; Gewirth DT; Mohler JL
Asian J Urol; 2019 Jan; 6(1):50-56. PubMed ID: 30775248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]